RALEIGH, N.C., Jan. 17, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that it has acquired exclusive U.S. rights to sell Soltamox™, a liquid formulation of tamoxifen for the treatment of breast cancer, through the acquisition of South Carolina-based specialty pharmaceutical company, Oncogenerix, Inc. Christopher Clement, CEO of Oncogenerix and former CEO of Savient Pharmaceuticals, will join DARA as a director and as Chief Operating Officer.